The FDA on September 14, 2021, granted accelerated approval to BRUKINSA® for adult patients with relapsed or refractory Marginal Zone Lymphoma (MZL) who have received at least one anti-CD20-based regimen. BRUKINSA® is a product of BeiGene.
Other Pages – Bottom Ad
Advertisement
Subscribe
